Growth factors and cytokines in autologous platelet concentrate and their correlation to periodontal regeneration outcomes. J Clin Periodontol

Department of Operative Dentistry and Periodontology, University of Regensburg, Regensburg, Germany.
Journal Of Clinical Periodontology (Impact Factor: 3.61). 11/2006; 33(11):837-45. DOI: 10.1111/j.1600-051X.2006.00991.x
Source: PubMed

ABSTRACT To determine the concentration of naturally available biologic mediators in autologous platelet concentrates and their correlation with periodontal regeneration outcomes.
In 25 patients with two intra-bony defects each, an autologous platelet concentrate (APC) was prepared by a laboratory thrombocyte apheresis technique pre-operatively. Both defects were treated using a bioresorbable guided tissue regeneration-membrane in combination with tricalciumphosphate (TCP). In the test defect, APC was additionally applied. In the APC, platelets were counted and the levels of growth factors and cytokines were determined by ELISA. Correlations between the platelet counts or the growth factor/cytokine levels and the potential clinical and radiographic regeneration outcomes due to APC were calculated after 3, 6, and 12 months.
The APC contained 2.2 x 10(6) platelets/mul, which was 7.9 times more than in the venous blood. Transforming growth factor-beta1 (TGF-beta1), insulin-like growth factor-I (IGF-I), platelet-derived growth factor-AB (PDGF-AB), PDGF-BB, vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) were found in the APC, whereas interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor alpha (TNFalpha), IL-4, and IL-10 were not detectable. The regression analysis showed a weak correlation between the platelet counts or the growth factor levels and the clinical and radiographic regeneration outcomes (r2<or=0.4).
Autologous platelet concentrate contains relatively high concentrations of PDGF-AB, PDGF-BB, TGF-beta1, and IGF-I, but their potential influence on periodontal regeneration remains unclear.

  • Source
    • "Se mantuvo la constante de que las mayores concentraciones de PDGFBB se presentaron en el PRP tanto antes como después del tratamiento, además los niveles promedio de PDGFBB antes del tratamiento fueron similares a los reportados por otros investigadores cuyos valores oscilaron entre 2,3 y 37 ng/ml. Entre dichos estudios, vale la pena mencionar el realizado por Christgau M y col (2006), quienes evaluaron los niveles de FC y citocinas en concentrados plaquetarios de donantes de sangre estableciendo su correlación con la regeneración periodontal. En este estudio los niveles de PDGFBB se situaron en 15,8 ± 7,9 ng/ml, considerándose dichos niveles elevados (30, 31, 35, 43, 44). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Niveles del factor de crecimiento derivado de plaquetas en el plasma rico en plaquetas antes y despues de antiagregantes plaquetarios (PDGF levels in platelet-rich plasma before and after anti platelets drugs)
  • Source
    • "The following GF were evaluated: platelet derived growth factor-AB and -BB (PDGF-AB, PDGF-BB), transforming growth factor-b1 and -b2 (TGF-b1, TGF-b2), epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), basic-fibroblast growth factor (b-FGF) and vascular endothelial growth factor (VEGF) [20] [21]. The contents of TGF-b1 and TGF-b2 were evaluated after acidic activation and neutralization of the samples, to change their latent forms into immune-reactive forms. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated growth factor contents and clinical efficacy of allogeneic platelet gel (PG) prepared with standard blood banking procedures from routine platelet concentrates (PCs) obtained from buffy coats. The PGs were used to treat 11 hypomobile very elderly patients unable to undergo autologous blood processing and previously ineffectively treated with expensive advanced medications for 8-275 weeks. PGs were prepared by platelet activation with human thrombin or commercial batroxobin. Median and range growth factor contents (ng/mL) were: platelet derived growth factor (PDGF-AB/-BB) 112 (31-157) and 20 (3.8-34); transforming growth factor (TGF-β1/-β2) 214 (48-289) and 0.087 (0.03-0.28); basic-fibroblast growth factor (b-FGF) 0.03 (0.006-0.214); vascular endothelial growth factor (VEGF) 1.15 (0.18-2.46); epidermal growth factor (EGF) 4.50 (0.87-6.64); insulin-like growth factor (IGF-l) 116 (72-156). In the clinical study, 222 PGs were used within 2 h of activation to treat 14 chronic skin ulcers in the 11 patients. No improvement was seen in 3 patients with 24, 27 and 30 cm(3) ulcers who could be treated for no more than 4, 7 and 8 weeks due to progressively worsening clinical conditions, while 11 ulcers with 3.2 cm(3) median size (range 0.2-3.6) in the remaining 8 patients showed 91 ± 14 % reduction after a median of 12 weeks (range 1-20). Cost of PG treatment (19,976 euro) amounted to about 10% of the ineffective advanced medication hospital reimbursement fees (191,236 euro). This study supports efficacy and feasibility of allogeneic PG to treat recalcitrant ulcers in very elderly hypomobile patients for whom autologous blood processing may be difficult.
    Biologicals 02/2011; 39(2):73-80. DOI:10.1016/j.biologicals.2011.01.002 · 1.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The purpose of this study was to compare the clinical effectiveness of two regenerative techniques for intrabony defects in humans: a combination of PRP versus a combination of PRP/DFDBA. Methods: The intrabony defects of thirty six patients participated in the study were surgically treated with either a combination of PRP or PRP/ DFDBA. The outcomes of the study included changes in probing depth, attachment level, and defect fill as revealed by clinical measurements and radiograms at 1 and 2 years post-treatment. Results: Clinical examination of the treated defects revealed that both treatment modalities resulted in significant probing depth reduction and clinical attachment gain compared to baseline values. There were statistical differences in PRP+DFDBA group compared to PRP in probing depth, attachment level, and defect fill. Conclusion: The results of this study showed that PRP and PRP/ DFDBA were both effective in the treatment of intrabony defects present in patients with advanced chronic periodontitis with narrow bone defects, but PRP/ DFDBA group was more effective than PRP.
Show more